Understanding Canagliflozin and SGLT2 Inhibition

Canagliflozin belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, a group of oral antihyperglycemic agents approved for managing type 2 diabetes. By selectively blocking SGLT2 proteins in the proximal renal tubule, the drug reduces glucose reabsorption, resulting in glycosuria and a consequent lowering of blood glucose levels. This mechanism also induces a mild osmotic diuresis, which can alter the electrolyte and mineral balance. The SGLT2 inhibitor class includes canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, with each exhibiting subtle differences in selectivity, pharmacokinetics, and adverse effect profiles.

Although canagliflozin effectively improves glycemic control, promotes weight loss, and reduces blood pressure, its safety profile has been closely scrutinized. One area of particular concern is the potential for adverse effects on bone health, including increased fracture risk and negative impacts on bone mineral density (BMD). The U.S. Food and Drug Administration (FDA) updated the prescribing information for canagliflozin in 2015 to include a warning about an increased risk of bone fractures, based on data from the CANagliflozin cardioVascular Assessment Study (CANVAS) program. Subsequent research has further explored these associations, making it essential for clinicians and patients to understand the underlying mechanisms and clinical implications.

The Clinical Evidence Linking Canagliflozin to Bone Fractures

Several large-scale clinical trials and observational studies have provided data on the relationship between canagliflozin use and fracture incidence. The most influential evidence comes from the CANVAS program, which integrated two sister trials—CANVAS and CANVAS-R—and included over 10,000 patients with type 2 diabetes and high cardiovascular risk.

CANVAS Program Findings

The CANVAS trial demonstrated a statistically significant increase in the risk of fractures, primarily in the upper and lower extremities, among patients treated with canagliflozin compared to placebo. The hazard ratio for all fractures was approximately 1.26 (95% CI, 1.01-1.57), with a notably higher risk observed in older patients and those with a history of cardiovascular disease or impaired renal function. Importantly, the increased fracture risk emerged early after initiation of therapy, suggesting mechanisms independent of cumulative dosing. The FDA’s analysis noted that the fractures were not associated with episodes of hypoglycemia or falls, pointing to a direct effect on bone structure or metabolism.

Meta-Analyses and Observational Studies

Subsequent meta-analyses of randomized controlled trials have reinforced these findings. A 2022 meta-analysis pooling data from over 30,000 participants reported a 23% increased risk of fractures with canagliflozin compared to placebo or other active comparators (risk ratio 1.23, 95% CI 1.04-1.45). In contrast, similar analyses for dapagliflozin and empagliflozin have not consistently shown the same risk elevation. Observational studies using real-world databases have partially corroborated the association, though some have found that the risk may be confined to patients with existing bone frailty or those taking loop diuretics concurrently. The diverging results across SGLT2 inhibitors highlight the importance of drug-specific evaluation and mechanistic understanding.

Subgroup Analyses and Risk Factors

Further analysis of CANVAS data revealed that fracture risk was particularly elevated in patients with baseline eGFR below 60 mL/min/1.73 m² and in those aged 65 years or older. Women also appeared to be more susceptible, possibly due to lower baseline BMD. A post-hoc analysis from the CANVAS program presented at the American Diabetes Association meeting in 2019 suggested that the risk was highest during the first 12 months of treatment, with a hazard ratio of 1.36 (95% CI 1.04-1.78). These findings underscore the need for early monitoring and risk stratification.

Proposed Mechanisms for Bone Health Effects

Several biological pathways have been proposed to explain the observed link between canagliflozin and adverse bone outcomes. These mechanisms involve alterations in mineral metabolism, endocrine regulation, and direct cellular effects on bone remodeling.

Alterations in Mineral Metabolism

Canagliflozin increases urinary excretion of glucose, sodium, and—to a lesser extent—calcium and magnesium. The mild diuretic effect can lead to a negative calcium balance over time, particularly in individuals with marginal dietary intake or vitamin D insufficiency. Chronic calcium loss may stimulate parathyroid hormone (PTH) secretion to maintain serum calcium, which in turn accelerates bone resorption. Similarly, magnesium depletion can impair osteoblast function and reduce bone formation. Evidence from small clinical studies shows that canagliflozin therapy is associated with increased serum phosphate levels, a known trigger for PTH release and fibroblast growth factor 23 (FGF23) production.

Effects on Parathyroid Hormone and Fibroblast Growth Factor 23

Elevated serum phosphate directly stimulates PTH and FGF23 secretion. PTH promotes osteoclast activity, leading to enhanced bone resorption and release of calcium into the circulation. FGF23, produced primarily by osteocytes, downregulates renal phosphate reabsorption and suppresses 1,25-dihydroxyvitamin D synthesis, further disrupting calcium-phosphate homeostasis. A cross-sectional study of patients with type 2 diabetes found that canagliflozin users had significantly higher serum FGF23 concentrations compared to those on other diabetes medications. This FGF23 elevation may independently correlate with increased fracture risk, as seen in chronic kidney disease populations. Additionally, some evidence suggests that canagliflozin directly affects osteocyte function, potentially altering the balance between bone formation and resorption.

Changes in Bone Turnover Markers

Bone turnover markers (BTMs) such as procollagen type 1 N-terminal propeptide (P1NP) and C-telopeptide of type 1 collagen (CTX) provide insight into dynamic bone remodeling. Limited data from randomized trials indicate that canagliflozin may increase markers of bone resorption (CTX) without a compensatory rise in formation markers (P1NP), suggesting an uncoupling of the remodeling process. This pattern mimics that of glucocorticoid-induced bone loss and is considered a risk factor for decreased bone mineral density. A small 12-week study reported a statistically significant increase in CTX levels in the canagliflozin group versus placebo, while levels of P1NP remained unchanged. Although these findings are preliminary, they support the hypothesis that canagliflozin exerts a direct catabolic effect on bone.

Direct Cellular Effects on Osteoblasts and Osteoclasts

Preclinical studies have investigated whether canagliflozin directly impacts bone cell function. In vitro experiments using human mesenchymal stem cells showed that canagliflozin, but not dapagliflozin or empagliflozin, inhibited osteoblast differentiation and mineralization at clinically relevant concentrations. This effect may be mediated through off-target inhibition of SGLT1 or alterations in intracellular sodium and calcium signaling. Additionally, some animal studies have reported increased osteoclast activity and cortical bone porosity in rats treated with canagliflozin. These direct cellular effects offer a plausible explanation for the drug-specific fracture risk observed in clinical trials.

Clinical Implications for Patients and Providers

Given the available evidence, the decision to prescribe canagliflozin must include a careful assessment of each patient’s bone health risk. Patients with preexisting osteoporosis, a history of low-trauma fractures, or advanced age are at heightened risk and may require additional monitoring or alternative medications.

Risk Stratification and Monitoring

Before initiating canagliflozin, clinicians should evaluate baseline fracture risk using validated tools such as the Fracture Risk Assessment Tool (FRAX). Measurement of serum calcium, phosphate, PTH, and 25-hydroxyvitamin D levels can identify subclinical abnormalities that might predispose to bone loss. In patients deemed to be at increased risk, periodic bone mineral density testing (DXA) and monitoring of bone turnover markers may be advisable, especially during the first year of therapy. It is also prudent to counsel patients about fall prevention and to review concurrent medications that may exacerbate bone loss, such as loop diuretics, proton pump inhibitors, or glucocorticoids.

Nutritional and Lifestyle Interventions

Ensuring adequate intake of calcium (1000–1200 mg per day) and vitamin D (600–800 IU per day) is fundamental for all patients on canagliflozin. For those with documented vitamin D deficiency, higher-dose supplementation may be necessary to maintain serum levels above 30 ng/mL. Weight-bearing exercises, resistance training, and balance activities should be encouraged to preserve bone mass and reduce fall risk. Smoking cessation and moderation of alcohol consumption are also essential, as these factors independently impair bone health.

Considerations for Switching Medications

If a patient experiences a fracture while on canagliflozin or develops significant bone density loss, switching to another SGLT2 inhibitor may be considered. The available data suggest that dapagliflozin and empagliflozin do not carry the same fracture risk, although long-term bone safety data are still limited. Alternative non-SGLT2 options include GLP-1 receptor agonists, DPP-4 inhibitors, or metformin, depending on the patient’s glycemic targets and cardiovascular/renal needs. Shared decision-making should incorporate the patient’s values and the relative importance of glycemic control versus bone safety.

Special Populations: Elderly and Renal Impairment

Elderly patients often have reduced renal function, lower BMD, and higher fall risk, making them particularly vulnerable to canagliflozin-induced fractures. The CANVAS data showed that patients aged ≥75 years had a fracture incidence of 3.1% with canagliflozin versus 1.9% with placebo. In patients with chronic kidney disease stage 3b or worse, the risk-benefit ratio becomes even more complex. Although canagliflozin provides renoprotective benefits in the CREDENCE trial, the fracture risk in this subgroup requires careful monitoring. For such patients, a multidisciplinary approach involving an endocrinologist, nephrologist, and primary care provider is recommended.

Comparative Bone Safety Across SGLT2 Inhibitors

The divergence in bone safety outcomes among SGLT2 inhibitors has attracted considerable attention. In contrast to canagliflozin, the EMPA-REG OUTCOME trial for empagliflozin did not report an increased fracture risk. Similarly, the DECLARE-TIMI 58 trial for dapagliflozin found no significant difference in fracture incidence between the active and placebo groups. A network meta-analysis published in Diabetes, Obesity and Metabolism (2023) indicated that the odds ratio for fractures was significantly higher only for canagliflozin compared to placebo (OR 1.29, 95% CI 1.08–1.54), while empagliflozin and dapagliflozin had odds ratios close to 1.0.

These differences may stem from variation in SGLT2 selectivity, off-target effects, or pharmacokinetic properties. Canagliflozin has a lower selectivity for SGLT2 over SGLT1 compared with other agents, potentially leading to greater gastrointestinal glucose loss and different metabolic consequences. Some preclinical studies suggest that canagliflozin, but not dapagliflozin or empagliflozin, can directly inhibit osteoblast proliferation and differentiation, possibly through changes in intracellular sodium concentrations or activation of proapoptotic pathways. More research is needed to clarify these drug-specific effects and to guide clinical decision-making.

Head-to-Head Comparisons in Real-World Data

Several large claims database studies have compared fracture rates across SGLT2 inhibitors. A cohort study using the U.S. Optum Clinformatics Data Mart found that canagliflozin users had a 30% higher risk of lower limb fractures compared to dapagliflozin users (adjusted HR 1.30, 95% CI 1.05-1.61). Another analysis from the Danish national registries reported no significant fracture risk difference between empagliflozin and dapagliflozin, but noted a small increased risk for canagliflozin versus empagliflozin in patients aged ≥65. These real-world findings align with clinical trial data and support the notion of a drug-specific effect.

Ongoing Research and Future Directions

Several ongoing studies are aimed at elucidating the long-term bone effects of canagliflozin and other SGLT2 inhibitors. The CANVAS program continues to collect long-term follow-up data, and new trials such as CREDENCE (focused on renal outcomes) are also analyzing secondary bone endpoints. Mechanistic studies using bone biopsy and advanced imaging techniques are underway to assess changes in microarchitecture and material properties. Additionally, pharmacogenomic investigations may identify subgroups of patients who are particularly susceptible to bone loss.

The development of newer SGLT2 inhibitors with improved selectivity profiles may reduce the risk of adverse bone effects. Meanwhile, clinicians can consult updated clinical practice guidelines from organizations such as the American Diabetes Association (ADA) and the American Association of Clinical Endocrinology (AACE) for recommendations on patient selection and monitoring. Future guidelines will likely incorporate fracture risk assessment into the pre-prescribing workup for canagliflozin specifically.

Emerging Therapeutic Approaches

Researchers are exploring whether combination therapy with bone-protective agents can mitigate canagliflozin-induced bone loss. For instance, the use of bisphosphonates or denosumab in patients requiring canagliflozin and at high fracture risk is being investigated. Additionally, studies on the role of calcium and vitamin D supplementation in preventing BMD decline during SGLT2 inhibitor therapy are ongoing. These approaches may allow continued use of canagliflozin in patients who derive substantial cardiovascular or renal benefit.

Conclusion

Canagliflozin remains a valuable therapeutic option for type 2 diabetes, offering benefits beyond glycemic control, including cardiovascular and renal protection. However, the evidence linking it to an increased risk of fractures and adverse bone health effects cannot be ignored. Multiple mechanisms—including altered mineral metabolism, elevated PTH and FGF23 levels, direct cellular effects on bone remodeling, and changes in bone turnover markers—likely contribute to this association.

For healthcare providers, the key takeaway is to perform a bone health assessment before initiating canagliflozin, especially in patients with preexisting risk factors. Regular monitoring of calcium, vitamin D, and PTH, along with lifestyle interventions and fall prevention, should be part of the management plan. If fractures or significant bone loss occur, a switch to another medication such as empagliflozin or dapagliflozin may be appropriate. Collaborative decision-making and continued vigilance will help balance the metabolic benefits of canagliflozin with the need to preserve skeletal health.

External References: